1

Impact of Vaccine Prioritization Strategies on Mitigating COVID-19: An Agent-Based Simulation Study using an Urban Region in the United States

Hanisha Tatapudi[1], Rachita Das[2], and Tapas K. Das [1]

[1] Department of Industrial and Management System Engineering, University of South Florida, Tampa, Florida, USA.

[2] Miller School of Medicine, University of Miami, Miami, Florida, USA.

Corresponding author: Hanisha Tatapudi

Email: tatapudi@usf.edu

ABSTRACT

Background

Approval of novel vaccines for COVID-19 has brought hope and expectations, but not without additional challenges. One central challenge is how to appropriately prioritize the use of limited supply of vaccines. This study examines the efficacy of the various vaccine prioritization strategies using the vaccination campaign underway in the U.S.

Methods

The study develops a granular agent-based simulation model for mimicking community spread of COVID-19 under various social interventions including full and partial closures, isolation and quarantine, use of face mask and contact tracing, and vaccination. The model is populated with parameters of disease natural history, as well as demographic and societal data for an urban community in the U.S. with 2.8 million residents. The model tracks daily numbers of infected, hospitalized, and deaths for all census age-groups. Model is calibrated using parameters for viral transmission and level of community circulation of individuals. Published data from the Florida COVID-19 dashboard is used to validate the model. Vaccination strategies are compared using hypothesis test for pairwise comparisons.

Results

Three prioritization strategies are examined: a minor variant of CDC's recommendation, an age-stratified strategy, and a random strategy. The impact of vaccination is also contrasted with a no vaccination scenario. The study shows that the ongoing campaign in the U.S. using vaccines developed by Pfizer/BioNTech and Moderna is expected to 1) reduce the cumulative number of infections by 10% and 2) help the pandemic to subside below a small threshold of 100 daily new reported cases sooner by approximately a month. A comparison of the prioritization strategies shows no significant difference in their impacts on pandemic mitigation.

Conclusions

Recent explosive growth of the number of new COVID-19 cases in the U.S. continues to shrink the susceptible population. A shrinking susceptible pool may be an attributable reason for the observed lack of statistical difference among the outcomes of the prioritization strategies. However, the invariance of the strategies offers more latitude to decision makers in COVID-19 vaccine distribution. For example, instead of adhering strictly to priority groups

54   sequentially (as in CDC variant), the approach of distributing vaccines among all elgibile as quickly as possible (as

55   in random strategy) is equally effective and also easier to implement.

57   Keywords: Vaccination strategies, COVID-19, Agent-based simulation model, Vaccination policies, Vaccination

58   prioritization

INTRODUCTION

SARS-CoV-2 and resulting COVID-19 disease has been raging world-wide since early 2020, killing over 2.0

million globally and nearly 450,000 in the United States by the end of January 2021 [1]. A significant winter swell

in cases is underway in the U.S. despite protective measures in place such as face mask usage, limited contact

tracing, travel restrictions, social distancing practices, and partial community closures. To combat this, many

promising novel vaccines have been under development, of which two (Pfizer/BioNTech and Moderna) have been

authorized for emergency use since mid-December 2020 by the U.S. Food and Drug Administration (USFDA) [2].

Data from initial trials of cohorts greater than 30,000 people showed that these vaccines, given in two doses, are safe

and have ~95% effectiveness in preventing COVID-19 [3]. Vaccine deployment in the U.S. began soon after

USFDA approval.

Implementing an effective vaccination campaign will be essential to dramatically reduce the infection,

hospitalization, and death rates, but it poses many unique challenges. Vaccine prioritization and allocation strategy

is at the forefront of the challenges to effectively vaccinate communities. Strategy is influenced by a number of key

factors: 1) limited initial vaccine supply in the months following release, 2) transmission and severity of COVID-19

varying by segment of the population, 3) vaccine approvals only for adults, and 4) acceptability and compliance in

the community for two dose vaccination [4].

U.S. Centers for Disease Control (CDC) has released an outline prioritizing healthcare personnel, first responders,

persons with high risk medical conditions for COVID-19, and older adults >65 years. These groups will be given

priority for vaccination in phase 1, when vaccine supply is still limited. In phase 2 (supply increases to begin to meet

demand) and phase 3 (supply is greater than demand) other population groups will begin to be vaccinated based on

age and availability [5]. Vaccine allocation structures with basic similarities and some key differences are being

used by countries around the world. For example, after healthcare workers, France's vaccine allocation is scheduled

to include other general workers regardless of age who they have determined to be at high risk of contracting and

spreading the virus due to contact with the general public. This includes retail, school, transportation, and hospitality

staff [6]. Such differences in vaccine prioritization strategies are as of yet untested and warrant modeling and

examination.

The goal of this paper is to investigate the impact of vaccination on the pandemic via outcome measures such as

numbers of infected, hospitalized, and deaths in the months following December 15, 2020 when vaccination begins

in the U.S. Two specific objectives of our investigation are: 1) to assess the expected impact of the vaccination

program on mitigating COVID-19, and 2) to inform public health officials on the comparative benefits, if any, of the

different vaccine prioritization strategies. We conduct our investigation by using our agent-based (AB) simulation

model for COVID-19 that was presented during the early phase of the pandemic [7]. For this study, we first extend

calibration of our model till December 30, 2020 to ensure that our model appropriately tracks the explosive increase

in cases that started with the onset of winter and the year-end holiday period. We then enhance the AB simulation

model by adding a framework for vaccination. This included: vaccination priorities for people based on attributes

including profession and age, use of two different vaccines by Pfizer/BioNTech and Moderna with their contracted

quantities and approximate delivery timelines, vaccine acceptance, transition period between each priority group,

vaccination rate, and immunity growth for vaccinated starting with the first dose.

As in [7], we implement our calibrated AB model, augmented with vaccination, for Miami-Dade County of the U.S.

with 2.8 million population, which has been an epicenter of COVID-19 in the U.S. We conduct our investigation by

implementing a number of prioritization strategies and obtaining the corresponding numbers of total infections,

reported infections, hospitalizations, and deaths. The strategies we implemented are 1) minor variant of the CDC

recommended strategy, 2) age stratified strategy, and 3) random strategy. We also implemented a no vaccination

case. These strategies are explained in a later section. We compare and contrast the results to assess vaccination

efficacy and relative performances of the priority strategies. We make a number of key observations from the

results, which we believe will help public health officials around the world to choose effective vaccine prioritization

strategies to mitigate the negative impacts of COVID-19.

LITERATURE REVIEW

On a global scale, equitable and ethical distribution of vaccines for all (low, medium, and high-income) countries is

an important question. As the world leader in promoting global health, World Health Organization (WHO) released

an evidence-based framework for vaccine-specific recommendations [8]. WHO proposed vaccine prioritization for

three potential scenarios of transmission: community transmission, sporadic cases or cluster of cases, and no cases.

Each scenario has three stages and focuses on different risk groups. COVID-19 pandemic resembles "community

transmission." For this, the first stage focuses on healthcare workers and older adults with highest risk; second stage

continues the focus on older adults and people with comorbidities, sociodemographic groups, and educational staff;

and the third stage focuses on essential workers and social/employment groups unable to physically distance

themselves.

National Academy of Sciences, Engineering, and Medicine (NAESM) developed a more comprehensive phased

framework for equitable allocation of COVID-19 vaccine [9]. The first phase prioritizes healthcare workers and first

responders, people with high risk comorbidities, and older adults in overcrowded living conditions; second phase

focuses on K-12 school staff and child care workers, essential workers, people with moderate risk comorbidities,

people living in shelters, physically and mentally disabled people and staff that provide care, employment settings

where social distancing is not possible, and remaining older adults; third phase prioritizes young adults, children,

and workers; and fourth phase includes everyone else. No specific studies have yet been presented to the literature

that evaluate the efficacy of the proposed vaccination priorities for mitigating COVID-19.

A number of studies can be found in the literature on vaccination strategies for controlling outbreaks of other

viruses. The work presented in [10] analyzes the effect of both CDC guided targeted vaccination strategy as well as

a mass vaccination strategy for seasonal Influenza outbreaks in the U.S. The study found that a mass vaccination

policy reaped the most benefits both in terms of cost and quality-of-life years (QALYs) lost. Authors in [11] use a

genetic algorithm to find optimal vaccine distribution strategies that minimize illness and death for Influenza

pandemics with age specific attack rates similar to the 1957–1958 A(H2N2) Asian Influenza pandemic and the

1968–1969 A(H3N2) Hong Kong Influenza pandemic. They consider coverage percentage under varying vaccine

availability and develop an optimal vaccination approach that is 84% more effective than random vaccination. A

study reported in [12] examined vaccination to prevent interpandemic Influenza for high-risk groups and children,

and recommended concentrating on schoolchildren, most responsible for transmission, and then extend to high-risk

groups. A compartmental model in [13] was used to develop optimal strategies to reduce the morbidity and mortality

of the H7N9 pandemic. The study found that age specific vaccination schedules had the most beneficial impact on

mortality.

It can be concluded from the above review of relevant literature that there is no 'one size fits all' strategy for

vaccination to either prevent a pandemic outbreak or mitigate one. Virus epidemiology and corresponding disease

characteristics, as well as the efficacy and supply of the vaccine must be considered in developing an effective

vaccination prioritization strategy. Our paper aims to address this need by presenting a detailed AB simulation

modeling approach and using it to assess efficacy of vaccine prioritization strategies for COVID-19.

METHODOLOGY

Published COVID-19 modeling approaches are either data-driven models, as in [14]–[18], or variants of SEIR type

compartmental models as in [19]–[23]. Data driven models are very well suited for understanding the past

progression of a pandemic and also for estimating parameters characterizing virus epidemiology. However, these

models offer limited ability to predict the future progression of a pandemic that is dynamically evolving with regards

to virus epidemiology, disease manifestations, and sociological conditions. Compartmental models, on the other

hand, are aggregate in nature and do not adapt well to changing dynamics of disease transmission. An AB modeling

approach is considered to be more suitable for a detailed accounting of individual attributes, specific disease natural

history, and complex social interventions [24]. Hence we adopted the AB model approach to conduct our study.

The AB simulation-based methodology is particularized using data for Miami Dade County of Florida, with 2.8

million population, an epicenter for COVID-19 spread in the South-Eastern United States. A step by step approach

for building such a model for another region can be found in [7]. The methodology begins by generating the

individual people according to the U.S. census data that gives population attributes including age (see Table A1 in

[7]) and occupational distribution (see Table A4 in [7]). Thereafter, it generates the households based on their

composition characterized by the number of adults and children (see Table A2 in [7]). The model also generates, per

census data, schools (see Table A3 in [7]) and the workplaces and other community locations (see Table A4 in [7]).

Each person is assigned a workplace and household based on the numbers, sizes, and compositions of households,

schools and workplaces derived from census data (see Tables A2, A3, and A4 in [7] for distribution of household,

schools, and workplaces, respectively). A daily (hour by hour) schedule is assigned to every individual, chosen from

a set of alternative schedules based on their attributes. The schedules vary between weekdays and weekends and also

depend on the prevailing social intervention orders (see Table A1 in Appendix). The methodology incorporates

means to implement a number of intervention orders including full and partial closures/reopening of schools and

workplaces [7], [25], isolation and quarantine of infected individuals and household members, use of face mask,

contact tracing of asymptomatic and pre-symptomatic individuals, and vaccination priorities. The timeline for

interventions implemented in the model are summarized in Table 1.

Table 1: Social intervention order timeline for Miami-Dade County

Intervention policy implemented at Miami-Dade County, Florida, U.S.	Date of implementation	Day of Simulation
Stay at home policy	March 17 2020	35
Phase I reopening	May 18 2020	97
Phase II reopening	June 5 2020	115
Mandatory usage of face mask	June 25 2020	135
Contact tracing (assumed to begin)	June 30 2020	140
Phase III reopening	September 25 2020	227
School reopening	September 30 2020	232
Vaccination begin day	December 15 2020	308

The AB model also includes a number of uncertainties such as 1) time varying values of testing rates for

symptomatic and asymptomatic, test sensitivity, and test result reporting delay (see Table A9 in [7]), 2) self-isolation

compliance for symptomatic cases and quarantine compliance for susceptible household members (see Table A10 in

[7]), 3) time varying and age specific probabilities of 'hospitalization among reported cases' and 'death among

hospitalized' (see Tables A2 and A3 in Appendix), 4) mask usage compliance (100% compliance is assumed to

reduce transmission coefficient by 33% [26]), 5) contact tracing level (assumed to be at 15% based on [27], [28]), 6)

percentage return to school (considred to be 50% based on [29]), 7) willingness to vaccinate (considered to be 60%

based on survey results in [30], [31]), 8) variations in daily schedules during various phases of social interventions

(see Table A5 in [7]), 9) percentage of asymptomatic among infected (assumed to be 35% [32]), and 10) vaccine

efficacy (95% [3]).

On the first day of the simulation, the model introduces a few initial infected cases in the community and begins the

social mixing process. Each day our model tracks the following for each person: 1) hourly movements and locations

based on their daily schedules that depend on age, employment status, prevailing social intervention orders, and

quarantine/isolation status; 2) hourly contacts with other susceptible and infected; 3) vaccination status and

immunity, 4) force of infection accumulation; 5) start of infection; 6) visits/consultation with a doctor (if symptomatic and insured); 7) testing (if infected and visited/consulted a doctor or asymptomatic chosen for testing either randomly or via contact tracing); 8) test reporting delay; 9) disease progression (if infected); 10) hospitalization (if infected and acutely ill); and 11) recovery or death (if infected). The AB model reports daily and cumulative values of actual infected, reported infections, hospitalized, and deaths, for each age category. A schematic diagram depicting the algorithmic sequence and parameter inputs for the AB simulation model is presented in Figure 1.

Figure 1: Schematic of the AB model for mimicking COVID-19 spread under social interventions and vaccination in the U.S.

223
224

For the susceptible, if vaccinated, since the exact immune response from vaccine is not known yet, we assume a

linearly increasing partial immunity for susceptible after they receive the first dose, attaining full immunity after

seven days after the second dose; we have so far only considered vaccines made by Pfizer/BioNTech and Moderna,

for which the second dose is administered 21 and 28 days after the first dose, respectively. The model updates the

infection status of all individuals to account for new infections as well as disease progressions of infected

individuals. A pseudo-code in Figure A1 (see Appendix) depicts the major elements and structure of the AB

simulation program.

For the infected, we consider the following epidemiological parameters: disease natural history with average lengths

of latent, incubation, symptomatic, and recovery periods; distribution of infectiousness; percent asymptomatic; and

fatality rate. The infected people are considered to follow a disease natural history as shown in Figure 2, parameters

of which can be found in Table A6 of [7]. The model assumes that the recovered cases become fully immune to

further COVID-19 infections. However, since this assumption is not fully supported yet by data, people recovered

from COVID-19 are also considered candidates for vaccination. The duration and intensity of infectiousness is

considered to be guided by a lognormal density function (see Figure 3). The function is truncated at the average

length of the infectiousness period (which is considered to be 9.5 days). Asymptomatic cases are assumed to follow

a similar infectiousness intensity profile but scaled by a factor   , as used in the force of infection calculation (1)

(see Table A4 in Appendix).

Figure 2: Disease natural history of COVID-19 [7]

Figure 3: Lognormal distribution function for infectiousness profile of a COVID-19 case [7]

In what follows we describe how we compute the force of infection and it's used in determining the probability of infection of individuals. Each susceptible is assumed to ingest viral particles from each infected they come in contact with during the day. The total amount of ingestion of viral particles for a susceptible i is measured as the force of infection (λ_i) using a modified version of the equation presented in [33]. The equation for force of infection (as presented in [33]) has three components to account for ingestions experienced from infected contacts at home, workplace/school/indoor community locations, and outdoor locations. As we did not find evidence in the literature of any significant COVID-19 transmissions at outdoor locations, we eliminated the third component and used only the first two elements of the equation as shown in (1). The first component of (1) accounts for the daily force of infection experienced by a susceptible i from those infected at home, and the second component accounts for workplace/school/indoor community locations.

$$\lambda_i = \sum_{k|h_k=h_i} \frac{I_k \beta_h \kappa(t-\tau_k)\rho_k[1+C_k(\omega-1)]}{n_i^\alpha} + \sum_{j,k|l_k^j=l_i^j} \frac{I_k \beta_p^j \kappa(t-\tau_k)\rho_k[1+C_k(\omega-1)]}{m_i^j} . \tag{1}$$

The definitions and values of parameters of (1) can be found in Table A4 in Appendix. The daily force of infection is considered to accumulate. However, it is assumed that if a susceptible does not gather any additional force of infection (i.e., does not come in contact with any infected) for two consecutive days, the cumulative force of infection for the susceptible reduces to zero. At the end of each day, the cumulative value of λ_i is used to calculate the probability of infection for susceptible i as $1 - exp^{-\lambda_i}$. This probability is used to classify a susceptible individual as infected in the simulation model.

As observed in [7], though it is implemented for a specific region, our model is quite general in its usability for other

urban regions with similar demography, societal characteristics, and intervention measures. In our model,

demographic inputs (age and household distribution, number of schools for various age groups, and number of

workplaces of various types and sizes) are curated from both national and local census records. Social interventions

vary from region to region and the related parameters can be easily updated. Similarly, the data related to

epidemiology of COVID-19 are unlikely to significantly vary from one region to another, though some adjustments

of these based on population demographics may be needed.

Model Calibration

The AB model utilizes a large number of parameters, which are *demographic*, *epidemiological*, and *social*

intervention parameters. We kept almost all of the above parameters fixed at their respective chosen values and

calibrated the model by changing values for only a few. The calibrated parameters include the transmission

coefficients used in calculating force of infection at home, work, school, and community places (β_h and β_p^j) (see

Table A4 in Appendix). The choice of the values of transmission coefficients was initially guided by [34] and

thereafter adjusted at different points in time during the calibration period (until December 30, 2020). The only other

parameters that were calibrated are the number of errands in the daily schedules under various intervention

conditions and the percentage of workers in essential (e.g., healthcare, utility services, and grocery stores) and non-

essential (e.g., offices and restaurants) workplaces who physically reported to work during different intervention

periods (see Table A1 in Appendix). Calibration of the above parameters was done so that the daily cumulative

numbers of reported infected cases from the AB simulation model closely match the values published in the Florida

COVID-19 dashboard until December 30, 2020. Figure 4 shows the cumulative values (with 95% confidence

intervals) as well as the daily numbers of the reported infected cases, hospitalizations, and deaths as obtained from

the simulation model. The dotted lines represent the actual numbers reported in the Florida COVID-19 dashboard

for Miami-Dade County [35], the trend of which is closely followed by the numbers obtained from our AB

simulation model. The actual numbers reported by the Florida COVID-19 dashboard show large variations, which is

due to reporting delays.

Figure 4: Validation graphs with cumulative and daily values of infected, reported, and deaths calibrated until Dec 30, 2020

VACCINE PRIORITIZATION STRATEGIES

We used our AB model to examine the expected benefits of the ongoing vaccination in the U.S. using the limited

supply of two types of vaccines developed by Pfizer/BioNTech and Moderna, which currently have the emergency

approvals for distribution. We considered the number of vaccine doses that the two companies are contracted by the

U.S. government to supply, which include the initial contracts for 100 million doses from each company and the

more recent contract for an additional 100 million doses from Pfizer/BoiNTech. This amounts to a total of 300

million doses, which can inoculate 150 million people with two required doses. To our knowledge, the total supply

is being apportioned among the states and the counties depending on the population. Florida has approximately

6.5% of the U.S. population and the Miami Dade County has 13% of Florida's population. Hence, we assumed that

Miami Dade County will receive approximately 2.54 million doses and be able to vaccinate 1.27 million people out

of the total 2.8 million population. We also assumed that the vaccine deliveries will occur in batches starting in late

December 2020 till late June 2021. Our study goal was to first determine the extent of reduction in the number of

infections, hospitalizations, and deaths that we can expect to realize from the vaccination process in comparison

with if no vaccines were available. Thereafter, we conducted a comparative study between three different

vaccination priority schemes to determine if the outcomes (number of reported cases, hospitalized, and deaths) from

those are statistically significant.

	Priority 1	Priority 2	Priority 3	Priority 4	Priority 5
Age stratified strategy	• Healthcare providers • Nursing home residents • *Dec 15, 2020 – Jan 13, 2021*	• People of ages 65 and over • *Jan 14 – Feb 12 2021*	• People of ages 55 to 64 • *Feb 13 – Mar 14 2021*	• People of ages 45 to 54 • *Mar 15 – Apr 13, 2021*	• People of ages 16 to 44 • *Apr 14 – Jul 15, 2021*
Minor CDC variant strategy	• Healthcare providers • Nursing home residents • *Dec 15, 2020 – Jan 13, 2021*	• First responders • Educators • People of ages 75 and over • *Jan 14 – Feb 12, 2021*	• People of ages 65 to 74 • *Feb 13 – Mar 30, 2021*	• People of ages 16 to 64 • *Apr 1 – Jul 15, 2021*	• NA
Random strategy	• Healthcare providers and nursing home residents • *Dec 15 2020 – Jan 13, 2020*	• All people of ages 16 and over • *Jan 14 – Jul 15, 2021*	• NA	• NA	• NA

316
317 **Figure 5:** Vaccine prioritization strategies examined using AB simulation model for COVID-19 in the U.S.
318

The priority strategies that were examined are broadly described here; a more complete description is presented in

Figure 5. In the absence of a declared timeline for transition of eligibility from one priority group to the next, we

assumed 30 days between transition. This period was extended to allow all eligible and willing to be vaccinated

when the phased vaccine supply fell short of the number of people in the eligible priority group. The first strategy

that we implemented is a minor ***variant of the CDC recommended strategy***: Priority 1: healthcare providers and

nursing home residents; Priority 2: first responders, educators, and people of ages 75 and over; Priority 3: people of

ages 65 to 74; Priority 4: people of ages 16 to 64. The CDC recommended strategy also includes in priority 3 people

of ages 16 to 64 with specific health conditions. Since we did not track health conditions in our AB model, we

limited our priority 3 to people of ages 65 and above only. The second strategy that we implemented is an ***age-***

stratified strategy: Priority 1: healthcare providers and nursing home residents; Priority 2: people of ages 65 and

over; Priority 3: people of ages 55 to 64; Priority 4: people of ages 45 to 54; Priority 5: people of ages 16 to 44. The

third strategy that we implemented is a ***random strategy***: Priority 1: healthcare providers and nursing home

residents; Priority 2: all people of ages 16 and over. People with prior COVID-19 history were not excluded and

60% of the people were considered willing to vaccinate [30], [31].

RESULTS

Figure 6 shows the plots indicating the growth over time in the number of actual reported vaccinations together with

those from the three vaccination prioritization strategies that we have implemented. The vaccination began on

December 15, 2020. Clearly the growth of the CDC variant strategy aligns closely with the acutal numbers. In the

random strategy, the growth in vaccination occurs faster as this strategy opens eligibility to all ages 16 and above

sooner than other strategies. The age dependent strategy further staggers the eligibility and hence the vaccination

grows slower than the CDC variant strategy. The flattening of the vaccination growth curves is representative of the

limited supply that was considered in our simulation. The continued growth of the acutal reported numbers is

indicative of the increase in vaccine supplies since the time of our model implementation in December 2020.

Figure 6: Cumulative values of actual reported and simulated vaccinations until July 31, 2021

Figure 7 shows the results obtained from the three vaccine prioritization strategies together with the no vaccination

scenario. The model predicted values of the cumulative numbers of infected cases, reported cases, hospitalized, and

deaths from the three policies on July 31, 2021 and their 95% confidence intervals are presented in Table 2. It also

provides the time frame when the pandemic is expected to subside with the new reported cases falling below the

threshold of 100. The reported cases presented in Figure 7 and Table 2 were obtained directly from the simulation,

as the simulation model was calibrated using the reported cases. However, the hospitalization and death numbers

were calculated by applying the time-varying and age-specific probabilities (presented in Tables A2 and A3 in

Appendix) on the reported cases.

Figure 7: Impact of vaccination strategies on cumulative numbers of infected, reported, hospitalized, and deaths from COVID-19 until July 31, 2021

358
359 **Table 2:** Summary of expected cumulative values (with 95% confidence intervals) on July 31, 2021 obtained by the
360 AB model for the vaccine prioritization strategies
361

Outcome Prioritization Strategy	Infected Cases	Reported Cases	Hospitalized	Deaths	Date when new reported cases fall below 100
No vaccination	1.71M (1.66M – 1.76M)	732K (695K – 770K)	18.7K (18.3K – 19.1K)	9K (8.8K – 9.3K)	June 12, 2021
Minor variant of CDC	1.55M (1.38M – 1.73M)	659K (567K – 752K)	17K (15.7k – 18.3k)	8K (7.2K – 8.8K)	May 17, 2021

Age stratified	1.58M (1.43M – 1.73M)	672K (589K – 754K)	17.6K (16.6k – 18.5k)	8.5K (7.9k – 8.9k)	May 22, 2021
Random	1.54M (1.32M – 1.75M)	649K (538K – 761K)	17.3K (15.9K – 18.7K)	8.4K (7.6K – 9.1K)	May 7, 2021

The performances of the three vaccine prioritization strategies, as seen in Figure 7 are comparable. Simple pairwise comparisons of the reported number of cases using a test of hypothesis showed that the variant of the CDC strategy produces a statistically significantly lower number of reported cases than the no vaccination (p-value 0.0204). Similar results were found for age-stratified and random strategies compared to no vaccination. However, a comparison among the three vaccine prioritization strategies showed no significant statistical difference among them for reported cases (p-values near 0.4). As expected, CDC variant strategy produced statistically significant lower numbers of hospitalized and deaths compared to no vaccination (p-values 0.0014 and 0.0015, respectively). Similar to the reported cases, the three vaccination strategies did not statistically differ in terms of hospitalizations and deaths.

The numbers from Table 2 indicate that the CDC variant strategy achieves a reduction of 9%, 10%, 9%, and 11% for total infected, reported cases, hospitalized, and deaths, respectively, compared to the outcomes with no vaccination. When compared to the no vaccination strategy, the CDC variant results in the pandemic subsiding below a small threshold (100) of new reported cases by May 16, 2021 (June 12, 2021 for no vaccination) and also spares 5.6% of the population form infection. This seemingly low impact of vaccination may be attributed to the fact that the trend of explosive growth of new cases in the winter months will have significantly reduced the pool of susceptible people by late spring, possibly approaching the 'herd immunity' state.

Figure 8: Visualization of the impacts of vaccination strategies on the percentage of total population infected and the total numbers of deaths on July 31, 2021

Figure 8 offers a further visual comparison of the impact of vaccination strategies on the percentage of population

infected and the total number of deaths. A few interesting observations can be made from the figure as follows. The

random strategy yields the lowest percentage of population infected (even lower than CDC variant) as it makes the

age groups most active in social mixing eligible sooner than all other strategies. For the same reason however, the

random strategy yields more deaths than CDC variant as it causes a delay in vaccination of the most vulnerable

elderly population who are not exclusively prioritized. According to our results, the random strategy performs better

than the age stratified strategy in both measures of performance, which may appear to be counterintuitive.

CONCLUDING REMARKS

We have developed a detailed AB simulation model for mimicking the spread of COVID-19 in an urban region

(Miami-Dade County, Florida) of the U.S. The model is calibrated using transmission coefficients and parameters

guiding daily schedules of the people and validated using the reported cases from the Florida COVID-19 dashboard

till December 30, 2020 (see Figure 4). On this validated model we have incorporated the vaccination process starting

in the U.S. on December 15, 2020 using two different vaccines developed by Pfizer/BioNTech and Moderna. Based

on the government contracts at the time of the study, we assumed availability of an estimated 2.54 million doses for

Miami-Dade county to inoculate 1.27 million people on a 2 dose regimen.

Model results indicate that the use of the available vaccines can reduce the spread of the virus and help the pandemic

to subside below a small threshold of daily new cases by mid-May 2021, approximately one month sooner than if no

vaccines were available. Also, the vaccination is expected to reduce number of infections by approximately 10%

compared to no vaccination, which translates to sparing 5.6% of the total population from being infected. We note

that, even though the vaccines were developed and approved for human use at a much faster rate than ever

accomplished before, the accelerated growth of the infections, especially with the onset of the winter in the northern

hemisphere, reduced the expected benefits of vaccination.

Another noteworthy finding of this study was that there was no statistical difference in number of reported cases

between vaccination prioritization strategies that are tested. This information can help give more latitude for

decision makers in COVID-19 vaccine distribution. Our results suggest that instead of adhering strictly to priority

groups sequentially, focus should be on distributing the vaccines among all elgibile as quickly as possible.

Though our AB model is well suited to study future progression of COVID-19, it has some limitations. As

mentioned under vaccination strategies, our model did not include health conditions that are relevant to COVID-19

(like pulmonary disease, obesity, heart problems) as attributes for people. Hence, we were not able to implement one

element of the CDC recommended prioritization strategy that includes people aged 16-64 years with underlying

medical conditions in priority 3. Also, we did not consider any vaccine wastage due to complexities associated with

refrigeration, distribution, and human error. We also assumed that vaccination of all priority groups will occur

uniformly over the eligibility periods considered, which may not reflect the reality. Also, since, to our knowledge,

there is little available literature on the rate of immunity growth each day from the two dose vaccines, we assumed a

linear growth starting with the first dose and culminating (full immunity) seven days after the second dose.

Moreover, as the pandemic progresses and new strains of the virus emerge, the level of immunity offered by the

vaccine for breakthrough infection may be lower. It is unclear how changes in the virus behavior might impact the

comparative outcomes of different vaccine prioritization strategies, as presented in this paper.

At the time of this study, since vaccine availability is still limited in many parts of the world, our results will provide

useful information for the healthcare policy makers in judiciously allocating their COVID-19 vaccine supply among

the population. We also believe that our findings on vaccine prioritization strategies will serve as a resource for the

decision makers for future outbreaks of similar respiratory viruses. Finally, as only a limited number of studies

examining vaccine prioritization strategies have been presented to the open literature, our research makes a

significant addition.

 LIST OF ABBREVIATIONS

AB – Agent-based

SEIR – Susceptible – exposed – infected – recovered/removed

SARS-CoV-2 – Severe acute respiratory syndrome coronavirus 2

COVID-19 – Coronavirus Disease 2019

USFDA – United States Food and Drug Administration

CDC – Centers for Disease Control

NAESM – NationalAcademy of Sciences, Engineering, and Medicine

QALY – Quality of Life Years

WHO – World Health Organization

463   DECLARATIONS

Ethics approval and consent to participate: Individual human data was not used in our study. Only aggregate data

made available in Florida COVID-19 Dashboard was used.

Consent for publication: Not applicable

Availability of data and materials: The datasets used and/or analysed during the current study are available from

the corresponding author on reasonable request.

Competing interests: The authors declare that they have no competing interests

Funding: Not applicable

Authors' contributions:

Hanisha Tatapudi: Conceived and designed the model, Selection of model input parameters and data gathering,

Coding and testing of the model, Design and perform the experiments, Output analysis and review, Manuscript

preparation and review

Rachita Das: Selection of model input parameters and data gathering, Output analysis and review, Manuscript

preparation and review

Tapas K Das: Conceived and designed the model, Selection of model input parameters and data gathering, Coding

and testing of the model, Design and perform the experiments, Output analysis and review, Manuscript preparation

and review

Acknowledgements: Not applicable

Authors' information:

Corresponding author:

Hanisha Tatapudi – corresponding author

e-mail: tatapudi@usf.edu.

Telephone: +1 (813) 453-3577

Rachita Das

e-mail: rachi95@gmail.com

Telephone: +1 (813) 527-1133

Tapas K. Das

e-mail: das@usf.edu

Telephone: +1 (813) 843-0285

REFERENCES

[1] A. Jordan *et al.*, "Coronavirus in the U.S.: Latest Map and Case Count," *NYtimes.com*, Jan. 25, 2021. Accessed: Jan. 25, 2021. [Online]. Available: https://www.nytimes.com/interactive/2020/us/coronavirus-us-cases.html

[2] "COVID-19 Vaccines," *U.S. Food & Drug Administration*, Jan. 12, 2021. Accessed: Jan. 25, 2021. [Online]. Available: https://www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/pfizer-biontech-covid-19-vaccine

[3] "Pfizer and BioNtech conclude Phase 3 study of COVID-19 vaccine candidate, meeting all primary efficacy endpoints," *Pfizer*, Nov. 18, 2020. Accessed: Jan. 25, 2021. [Online]. Available: https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-conclude-phase-3-study-covid-19-vaccine

[4] J. Buckner, G. Chowell, and M. Springborn, "Optimal Dynamic Prioritization of Scarce COVID-19 Vaccines," *Medrxiv*, Sep. 2020, doi: 10.1101/2020.09.22.20199174.

[5] "How CDC Is Making COVID-19 Vaccine Recommendations," *CDC*, Dec. 30, 2020. Accessed: Jan. 25, 2021. [Online]. Available: https://www.cdc.gov/coronavirus/2019-ncov/vaccines/recommendations-process.html

[6] L. Roope, P. Clarke, and R. Duch, "Who should get the coronavirus vaccine first? France and the UK have different answers," *The Conservation*, Nov. 16, 2020. Accessed: Jan. 25, 2021. [Online]. Available: https://theconversation.com/who-should-get-the-coronavirus-vaccine-first-france-and-the-uk-have-different-answers-149875

[7] H. Tatapudi, R. Das, and T. Das, "Impact assessment of full and partial stay-at-home orders, face mask usage, and contact tracing: An agent-based simulation study of COVID-19 for an urban region," *Glob. Epidemiol.*, vol. 2, no. 100036, Nov. 2020, doi: https://doi.org/10.1016/j.gloepi.2020.100036.

[8] "Evidence to recommendations for COVID-19 vaccines: Evidence framework," *WHO*, Dec. 10, 2020. Accessed: Jan. 25, 2020. [Online]. Available: https://www.who.int/publications/i/item/WHO-2019-nCoV-SAGE-Framework-Evidence-2020-1

[9] "Framework for equitable allocation of COVID-19 vaccine." The National Academy Press. Accessed: Jan. 25, 2021. [Online]. Available: https://www.nap.edu/read/25917/chapter/1

[10] K. Clements, J. Chancellor, N. Kristin, K. DeLong, and D. Thompson, "Cost-Effectiveness of a Recommendation of Universal Mass Vaccination for Seasonal Influenza in the United States," *Value Health*, vol. 14, no. 6, pp. 800–811, Sep. 2011, doi: https://doi.org/10.1016/j.jval.2011.03.005.

[11] R. Patel, I. Longini, and E. Halloran, "Finding optimal vaccination strategies for pandemic influenza using genetic algorithms," *J. Theor. Biol.*, vol. 234, no. 2, pp. 201–212, May 2005, doi: https://doi.org/10.1016/j.jtbi.2004.11.032.

[12] I. Longini and E. Halloran, "Strategy for Distribution of Influenza Vaccine to High-Risk Groups and Children," *Am. J. Epidemiol.*, vol. 161, no. 4, pp. 303–306, Feb. 2005, doi: https://doi.org/10.1093/aje/kwi053.

[13] D. Knipl and G. Röst, "Modelling the strategies for age specific vaccination scheduling during influenza pandemic outbreaks," *Math Biosci Eng*, vol. 8, no. 11, pp. 123–139, Jan. 2011, doi: 10.3934/mbe.2011.8.123.

[14] G. Barmparis and G. Tsironis, "Estimating the infection horizon of COVID-19 in eight countries with a data-driven approach," *135*, vol. 109842, May 2020, doi: 10.1016/j.[s.2020.109842.

[15] D. Candido, I. Claro, J. Jesus, W. Marciel de Souza, F. Moreira, and S. Dellicour, "Evolution and epidemic spread of SARS-CoV-2 in Brazil," *Science*, vol. 369, no. 6508, pp. 1255–1260, Sep. 2020, doi: 10.1126/science.abd2161.

[16] N. Chintalapudi, G. Battineni, and F. Amentaa, "COVID-19 virus outbreak forecasting of registered and recovered cases after sixty day lockdown in Italy: A data driven model approach," *J Microbiol Immunol Infect*, vol. 53, no. 3, pp. 396–403, Jun. 2020, doi: 10.1016/j.jmii.2020.04.004.

[17] Y. Fang, Y. Nie, and M. Penny, "Transmission dynamics of the COVID‐19 outbreak and effectiveness of government interventions: A data‐driven analysis," *J Med Virol*, vol. 92, no. 6, pp. 645–659, doi: 10.1002/jmv.25750.

[18] S. Yang, P. Cao, P. Du, Z. Wu, Z. Zhang, and L. Yang, "Early estimation of the case fatality rate of COVID-19 in mainland China: a data-driven analysis," *Ann Transl Med*, vol. 8, no. 4, p. 128, Feb. 2020, doi: 10.21037/atm.2020.02.66.

[19] A. Aleta, D. Martin-Corral, A. Piontti, M. AJelli, M. Litvinova, and M. Chinazzi, "Modeling the impact of
social distancing, testing, contact tracing and household quarantine on second-wave scenarios of the COVID-
19 epidemic," *Medrxiv*, May 2020, doi: https://doi.org/10.1101/2020.05.06.20092841.
[20] C. Hou, J. Chen, Y. Zhou, L. Hua, J. Yuan, and S. He, "The effectiveness of quarantine of Wuhan city against
the Corona Virus Disease 2019 (COVID□19): A well□mixed SEIR model analysis," *J Med Virol*, vol. 92, no.
7, pp. 841–848, Jul. 2020, doi: https://doi.org/10.1002/jmv.25827.
[21] L. Peng, W. Yang, D. Zhang, C. Zhuge, and L. Hong, "Epidemic analysis of COVID-19 in China by
dynamical modeling," *MedRxiv*, Feb. 2020, doi: https://doi.org/10.1101/2020.02.16.20023465.
[22] Z. Yang, Z. Zeng, K. Wang, S. Wong, W. Liang, and M. Zanin, "Modified SEIR and AI prediction of the
epidemics trend of COVID-19 in China under public health interventions," *J Thorac Dis*, vol. 12, no. 3, pp.
165–174, Mar. 2020, doi: 10.21037/jtd.2020.02.64.
[23] Y. Zhang, B. Jiang, J. Yuan, and Y. Tao, "The impact of social distancing and epicenter lockdown on the
COVID-19 epidemic in mainland China: A data-driven SEIQR model study," *MedRxiv*, Mar. 2020, doi:
https://doi.org/10.1101/2020.03.04.20031187.
[24] D. Chao, E. Halloran, V. Obenchain, and I. Longini, "FluTE, a publicly available stochastic influenza
epidemic simulation model," *PLoS Comput Biol*, vol. 6, no. 1, p. e1000656, Jan. 2010, doi:
10.1371/journal.pcbi.1000656.
[25] H. Tatapudi and T. K. Das, "Impact of school reopening on pandemic spread: A case study using an agent-
based model for COVID-19," *Infect. Dis. Model.*, vol. 6, pp. 839–847, 2021, doi: 10.1016/j.idm.2021.06.007.
[26] D. K. Chu *et al.*, "Physical distancing, face masks, and eye protection to prevent person-to-person
transmission of SARS-CoV-2 and COVID-19: a systematic review and meta-analysis," *The Lancet*, vol. 395,
no. 10242, pp. 1973–1987, Jun. 2020, doi: 10.1016/S0140-6736(20)31142-9.
[27] C. Vazquez, "Coronavirus in Miami-Dade: Contact tracing failures and talk of how to spend federal money,"
Local10, Jul. 27, 2020. https://www.local10.com/news/local/2020/07/27/coronavirus-in-miami-dade-contact-
tracing-failures-and-talk-of-how-to-spend-federal-money/ (accessed Jul. 30, 2021).
[28] "Contact Tracing Is Failing in Many States. Here's Why," *NY Times*, Jul. 31, 2020.
https://www.nytimes.com/2020/07/31/health/covid-contact-tracing-tests.html (accessed Jul. 30, 2021).
[29] Miami-Dade County Public Schools, "A guide to the reopening of Miami-Dade County public schools,"
Reopen smart return safe, Aug. 2020.
http://pdfs.dadeschools.net/reopening/Reopen%20SMART%20Return%20SAFE%20-
%20A%20Guide%20to%20the%20Reopening%20of%20Miami-Dade%20County%20Public%20Schools.pdf
(accessed Aug. 03, 2021).
[30] M. Beusokem, "Survey: COVID vaccine willingness waned since April," *Center for Infectious Disease
Research and Policy*, Dec. 30, 2020. Accessed: Jan. 28, 2021. [Online]. Available:
https://www.cidrap.umn.edu/news-perspective/2020/12/survey-covid-vaccine-willingness-waned-april
[31] L. Saad, "U.S. Readiness to Get COVID-19 Vaccine Steadies at 65%," *Gallup News*, Jan. 12, 2021. Accessed:
Jan. 28, 2021. [Online]. Available: https://news.gallup.com/poll/328415/readiness-covid-vaccine-
steadies.aspx
[32] CDC, "COVID-19 Pandemic Planning Scenarios," *Centers for Disease Control and Prevention*.
https://www.cdc.gov/coronavirus/2019-ncov/hcp/planning-scenarios-archive/planning-scenarios-2020-05-
20.pdf (accessed May 05, 2021).
[33] N. M. Ferguson *et al.*, "Strategies for containing an emerging influenza pandemic in Southeast Asia," *Nature*,
vol. 437, no. 7056, pp. 209–214, Sep. 2005, doi: 10.1038/nature04017.
[34] N. Ferguson, D. Cummings, C. Fraser, J. Cajka, P. Cooley, and D. Burke, "Estimating disease burden of a
potential A(H7N9) pandemic influenza outbreak in the United States," *Nature*, vol. 442, no. 7101, pp. 448–
452, Apr. 2006, doi: https://doi.org/10.1038/nature04795.
[35] "Florida's COVID-19 Data and Surveillance Dashboard," *Florida Department of Health, Division of Disease
Control and Health Protection*.
[36] "Evidence summary for COVID-19 viral load over course of infection," *Health Information and Quality
Authority*, 2020. https://www.hiqa.ie/sites/default/files/2020-04/Evidence-Summary_COVID-19_duration-of-
infectivity-viral-load_0.pdf (accessed Jul. 30, 2021).
602